

RESPIRATORY MEDICINE

Diagnostic Approach to the Coughing Cat

Jordan Gagne, DVM, DABVP (Canine/Feline Practice), DABVP (Feline Practice)
Salem Animal Rescue League, Salem, New Hampshire

The coughing cat presents a clinical challenge. Coughing is a nonspecific clinical sign, and differentials include infectious conditions such as viral, bacterial, and parasitic disease; neoplasia; and noninfectious feline lower airway disease (FLAD), which includes classic feline asthma, bronchiectasis, and chronic bronchitis. Cardiogenic disease rarely causes coughing as a primary clinical sign in cats but should remain a differential.

Initial assessment of patient signalment, history, and physical examination findings should consider patient lifestyle risk factors; the character of the cough; the presence of pyrexia; respiratory rate and effort; and 4-quadrant lung auscultation for abnormal sounds such as crackles, wheezes, or rales. If the patient is in respiratory distress, all other diagnostics must wait until the patient has been stabilized. In emergent cases, or those in which cost constrains a full diagnostic workup, therapeutic drug trials may be necessary.

Cats with FLAD often have lung hyperinflation and a diffuse bronchial or bronchointerstitial pattern, resulting in a classic “donut” or “tram line” effect due to bronchial wall thickening.

In all other cases, thoracic radiography is the next essential step in the diagnostic workup of a coughing cat. Assessment of lung pattern and distribution of pattern can quickly narrow the differential list. Cats with FLAD often have lung hyperinflation and a diffuse bronchial or bronchointerstitial pattern, resulting in a classic “donut” or “tram line” effect due to bronchial wall thickening. Radiographically, parasitic disease may appear similar. Cats with pneumonia may be more likely to present with an interstitial to alveolar lung pattern that is most likely to affect the ventral lung fields.

Blood analysis is useful to evaluate a patient's overall health status, and heartworm antibody and antigen testing should be performed as part of this assessment. Approximately 14% to 40% of cats with FLAD may have peripheral eosinophilia on CBC.^{1,2} Eosinophilia on CBC should increase suspicion for FLAD or parasitic causes of cough. A neutrophilic inflammatory leukogram is more commonly encountered in cases of infection.³

If the patient is clinically stable, the next diagnostic step after obtaining an initial radiographic assessment and establishing overall health status is lower airway sampling. Blind bronchoalveolar lavage (BAL) techniques are well described in the literature, are readily accessible, and show similar sample quality to that of bronchoscopically guided techniques.⁴ Fluid sample evaluation includes cell count, cytology, and culture. Cats in significant respiratory distress are not candidates for BAL. Evaluation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) level at the start of the diagnostic workup for a coughing cat can be useful in decreasing clinical suspicion for cardiogenic disease as a differential and establishing stability for undergoing anesthesia for BAL.

BOX 1**Diagnostic Database for the Coughing Cat*****1. Clinical assessment**

- a. Physical examination findings
- b. Patient history
- c. Patient signalment

2. Thoracic radiography**3. Blood analysis/serology**

- a. CBC
- b. Serum chemistry panel
- c. Heartworm antibody and antigen testing
- d. Feline NT-proBNP

4. Bronchoalveolar lavage

- a. Cytology
- b. Cell count
- c. Culture

5. Other

- a. Baermann fecal sampling for lungworm suspicion
- b. Fungal testing in endemic regions if radiographic signs are consistent

NT-proBNP = N-terminal pro-B-type natriuretic peptide.

**While obtaining a comprehensive database is preferred, ancillary diagnostics can be tailored based on the increase in clinical suspicion at each step.*

Developing a streamlined but comprehensive diagnostic approach that considers patient clinical history, physical examination findings, radiographic evaluation, blood analysis, parasite testing results, and

lower airway sampling is essential to obtaining an accurate diagnosis (**BOX 1**) and informing an effective therapeutic plan.

KNOW THE BOND.



**Human
Animal
Bond
Certified**


This course was designed in partnership with the Human-Animal Bond Research Institute to help explain what the bond is, how it works, and to demonstrate the role veterinary professionals play in supporting and strengthening its effects.




Get certified today!



GROW THE BOND.





FLAD = feline lower airway disease; HARD = heartworm-associated respiratory disease; NPS = no parasite seen; NT-proBNP = N-terminal pro-B-type natriuretic peptide.

^aThese are only general guidelines. Other patterns may be seen, and other conditions may cause coughing in cats. For example, a cat with severe chronic bronchitis may have an alveolar component.

^bOropharyngeal contamination may yield false-positive bronchoalveolar lavage culture results. Critically consider positive results within clinical context.



Scan to download PDF
Access a version of this
algorithm on your device.

References

1. Lee EA, Johnson LR, Johnson EG, Vernau W. Clinical features and radiographic findings in cats with eosinophilic, neutrophilic, and mixed airway inflammation (2011-2018). *J Vet Intern Med.* 2020;34(3):1291-1299. doi:10.1111/jvim.15772
2. Lin CH, Wu HD, Lee JJ, Liu CH. Functional phenotype and its correlation with therapeutic response and inflammatory type of bronchoalveolar lavage fluid in feline lower airway disease. *J Vet Intern Med.* 2015;29(1):88-96. doi:10.1111/jvim.12494
3. Dear JD, Vernau W, Johnson EG, Hulsebosch SE, Johnson LR. Clinicopathologic and radiographic features in 33 cats with aspiration and 26 cats with bronchopneumonia (2007-2017). *J Vet Intern Med.* 2021;35(1):480-489. doi:10.1111/jvim.16005
4. Hooi KS, Defarges AM, Sanchez AL, et al. Comparison of bronchoscopic and nonbronchoscopic bronchoalveolar lavage in healthy cats. *Am J Vet Res.* 2018;79(11):1209-1216. doi:10.2460/ajvr.79.11.1209
5. Nelson CT, McCall JW, Moorhead A, et al. American Heartworm Society feline guidelines for the prevention, diagnosis, and management of heartworm (*Dirofilaria immitis*) infection in cats. American Heartworm Society. Updated 2024. Accessed December 2, 2025. <https://www.heartwormsociety.org/veterinary-resources/american-heartworm-society-guidelines>

Author



Jordan Gagne

Dr. Gagne received her veterinary degree from Iowa State University's College of Veterinary Medicine and completed her American Board of Veterinary Practitioners residency in canine and feline practice at Weare Animal Hospital in New Hampshire. She is a member of the Feline VMA, ASV, AVMA, and IVAPM with special interests in cardiology, respiratory disease, and shelter medicine. Dr. Gagne is currently serving as the Director of Veterinary Services for Salem Animal Rescue League, a nonprofit organization dedicated to promoting animal welfare, reducing pet overpopulation, and providing access to veterinary care for underserved communities in the area.

FELYCIN®-CA1 (sirolimus delayed-release tablets)

Cardiac drug for oral use in cats only.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-604. It is a violation of federal law to use this product other than as directed in the labeling. For complete prescribing information, see full package insert. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. **Indication:** for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). **Dosage and Administration:** Administer Felycin-CA1 at a target dose of 0.3 mg/kg orally once weekly. Tablets should be swallowed whole and not chewed. Do not split or crush tablets. Felycin-CA1 should be administered with a meal. Cats weighing less than 2.5 kg cannot be accurately dosed. **Contraindications:** Felycin-CA1 should not be used in cats with diabetes mellitus. Discontinue immediately if a cat receiving Felycin-CA1 is diagnosed with diabetes mellitus. The administration of Felycin-CA1 to a cat that developed diabetes mellitus was associated with the development of diabetic ketoacidosis and death. Do not administer in cats with pre-existing liver disease. **User Safety Warnings:** Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. Pregnant and breastfeeding women should avoid contact with Felycin-CA1. People with known hypersensitivity to sirolimus should administer Felycin-CA1 with caution. **Animal Safety Warnings:** Administration of Felycin-CA1 with drugs that inhibit cytochrome P-450 3A4 or P-glycoprotein, such as calcium channel blockers, amiodarone, azoles, or cyclosporine, may increase risk for toxicity. Use caution when administering in cats with the MDR1 mutation or when administering concomitantly with another P-gp substrate. Treatment with Felycin-CA1 could impact the cat's ability to mount an adequate immune response to vaccinations. Concurrent administration of Felycin-CA1 did not impact the cat's ability to mount an adequate immune response to a killed rabies vaccine. The impact of Felycin-CA1 for FHV-1, FCV, FPV, and FeLV has not been evaluated. Keep Felycin-CA1 in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. **Precautions:** For use only in otherwise healthy cats with subclinical HCM in the absence of other causes of compensatory myocardial hypertrophy (e.g. systemic hypertension), current or historic symptoms of congestive heart failure, arterial thromboembolism, and severe LV outflow tract obstruction. Treatment with Felycin-CA1 has been associated with the elevation of the transaminase enzymes, which include alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The use of Felycin-CA1 in cats with viral disease like feline viral rhinotracheitis has not been evaluated. The safety and effectiveness of Felycin-CA1 has not been evaluated in cats with other cardiomyopathy phenotypes, in cats receiving beta blockers or corticosteroids, in cats with kidney disease, hyperthyroidism, or other significant systemic disease. The effectiveness of Felycin-CA1 has not been evaluated in sexually intact cats, therefore, should not be used in animals intended for breeding. **Adverse Reactions:** In a well-controlled pilot field study, 43 cats with subclinical HCM were administered either the label dose of Felycin-CA1 (0.3 mg/kg once weekly), twice the label dose (0.6 mg/kg once weekly), or a placebo control tablet and followed for 180 days or until removal from the study. The most frequently observed adverse reactions were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions were lethargy, vomiting, diarrhea, and inappetence. **Clinical Pharmacology:** Sirolimus is an immunosuppressant that targets and inhibits the mammalian target of rapamycin C1 (mTORC1) protein complex, a central regulator of cell growth and nutrient response. Studies in rodent models suggest mTOR inhibition by sirolimus attenuates cardiac hypertrophy by promoting autophagy, attenuating oxidative stress and blocking proinflammatory responses, thereby resulting in an improvement in cardiac function in rodents. **Reasonable Expectation of Effectiveness:** This product is conditionally approved by FDA pending a full demonstration of effectiveness. **To obtain full product information for Felycin-CA1 please call 1-800-874-9764.**

Manufactured for: PRN™ Pharmacal, Pensacola, FL 32514

PRN™ is a trademark of Pegasus Laboratories, Inc.

Dosage and Administration: For use in cats only. The total recommended dosage for Felycin-CA1 is 0.3 mg/kg once per week, dosed in conjunction with a meal. **Storage:** Store at 20-25°C (68-77°F). **WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.**